Friday, March 23, 2012

Copaxone generics - The market is getting increasingly competitive and restricted

There are much hopes tied around Copaxone generics for  Natco/Mylan, but there is an increasing number of players  targeting this market, which I think would spoil the party.  Besides Sandoz/Momenta, the first to file which obviously will enjoy the 180-days exclusivity, there is Synthon as well vying for Copaxone generics. Synthon has filed an ANDA in 2011. An authorized generic should also be expected.

Besides generics, competition is also anticipated from pipeline compounds (BG-12 and a new dosing version of Copaxone)